GO:0006957 complement activation, alternative pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006957 describes the alternative pathway of complement, a spontaneous and antibody-independent cascade that directly kills microbes and regulates other immune processes.
• The alternative pathway is initiated by tickover, the slow hydrolysis of C3 to C3(H2O), which forms a fluid-phase C3 convertase with factor B and factor D.
• Properdin stabilizes the alternative pathway C3 convertase on surfaces, while factor H, factor I, and MCP/DAF/CD59 restrain it to prevent host damage.
• Alternative pathway activation predicts renal outcome in lupus nephritis and contributes to thrombotic microangiopathy, thoracic aortic aneurysm/dissection, and COVID-19 microthrombosis [1,2,7,8].
• Low-molecular-weight inhibitors of the alternative pathway are being developed as therapeutic tools for complement-driven diseases.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal testing of alternative pathway genes in disease-relevant cell types [1,2,6].
Description
The complement system is a central arm of innate immunity, and the alternative pathway (AP) is unique because it can be activated without antibody or lectin engagement. GO:0006957, complement activation, alternative pathway, captures the biological process by which this spontaneous cascade is triggered and amplified, leading to direct killing of microbes and regulation of other immune processes [3,4]. The AP is now recognized not only as a first-line defense against pathogens but also as a driver of sterile inflammation in cardiovascular, renal, and thrombotic diseases [1,2,7,8]. For researchers, GO:0006957 provides a precise ontology anchor for interpreting transcriptomic, proteomic, and functional data in complement-related studies. Understanding the AP is essential because its dysregulation is implicated in conditions as diverse as lupus nephritis, atypical hemolytic uremic syndrome, age-related macular degeneration, and COVID-19-associated microthrombosis [2,7,8]. This article reviews the mechanism, key genes, disease links, and experimental models for studying GO:0006957, with a focus on CRISPR-based approaches for causal gene validation.
complement activation, alternative pathway At A Glance
| GO ID | GO:0006957 |
|---|---|
| GO term | complement activation, alternative pathway |
| Ontology | biological_process |
| Synonym | complement cascade, alternative pathway |
| Definition | Any process involved in the activation of any of the steps of the alternative pathway of the complement cascade which allows for the direct killing of microbes and the regulation of other immune processes. |
| Major function | Antibody-independent initiation and amplification of complement, leading to opsonization, lysis, and immune regulation [3,4]. |
| Key initiator | Spontaneous hydrolysis of C3 (tickover) to C3(H2O). |
| Key convertases | C3 convertase (C3bBb) and C5 convertase (C3bBbC3b) [3,4]. |
| Major regulators | Factor H, factor I, properdin, MCP (CD46), DAF (CD55), CD59. |
| Disease relevance | Lupus nephritis, thrombotic microangiopathy, thoracic aortic aneurysm/dissection, COVID-19 microthrombosis [1,2,7,8]. |
What Is GO:0006957?
GO:0006957, complement activation, alternative pathway, is defined by QuickGO as any process involved in the activation of any of the steps of the alternative pathway of the complement cascade which allows for the direct killing of microbes and the regulation of other immune processes. In practice, this includes the spontaneous hydrolysis of C3 (tickover), assembly of the alternative pathway C3 convertase (C3bBb), amplification of C3b deposition on surfaces, formation of the C5 convertase, and the downstream membrane attack complex, as well as the regulatory proteins that control these steps [3,4].
Why Is complement activation, alternative pathway Important in Cell Biology?
GO:0006957 is important because the alternative pathway is a dominant amplifier of complement activity in vivo and is increasingly recognized as a therapeutic target in inflammatory and thrombotic diseases [4,6]. Unlike the classical pathway, the AP does not require antibodies, so it can drive tissue injury rapidly in conditions such as lupus nephritis, thrombotic microangiopathy, and COVID-19-associated microthrombosis [2,7,8]. In thoracic aortic aneurysm/dissection, AP activation modulates inflammation and may influence disease progression. Because AP activation predicts renal outcome in lupus nephritis, it has potential as a biomarker and as a target for intervention. Low-molecular-weight AP inhibitors are being developed, highlighting the translational importance of understanding this pathway.
• Provides antibody-independent first-line defense against microbes through direct lysis and opsonization.
• Amplifies complement activation initiated by any pathway, making it a central hub of complement activity.
• Predicts renal outcome in lupus nephritis, supporting its use as a clinical biomarker.
• Contributes to thrombotic microangiopathy in lupus nephritis, a severe renal complication.
• Modulates inflammation in thoracic aortic aneurysm/dissection, linking complement to vascular disease.
• Drives microthrombosis in COVID-19 under cytokine storm conditions.
• Is a target for low-molecular-weight inhibitors, offering new therapeutic options.
• Requires tight regulation by factor H, factor I, MCP, DAF, and CD59 to prevent host tissue damage.
• Can be studied with CRISPR knockout, point-mutation, knock-in, and overexpression models for causal inference [1,2,6].
• Serves as a model system for understanding spontaneous protein activation and amplification cascades.
What Happens During complement activation, alternative pathway?
Initiation by tickover
In simple terms: The alternative pathway starts on its own when C3 spontaneously changes shape in the blood.
The alternative pathway is initiated by tickover, a continuous low-level spontaneous hydrolysis of the thioester bond in C3 to form C3(H2O). This conformational change allows C3(H2O) to bind factor B, which is then cleaved by factor D to form the fluid-phase C3 convertase C3(H2O)Bb. This initial convertase generates small amounts of C3b that can deposit on nearby surfaces, providing the seed for amplification. The history of the tickover concept shows that this spontaneous initiation is a fundamental property of the AP and explains its antibody-independent nature.
Amplification and C3 convertase assembly
In simple terms: Once C3b lands on a surface, it recruits more factors to build a powerful enzyme that coats the target with more C3b.
Surface-bound C3b binds factor B, which is cleaved by factor D to form the alternative pathway C3 convertase, C3bBb [3,4]. This convertase cleaves additional C3 into C3b, creating a positive feedback amplification loop that rapidly deposits C3b on microbial or damaged host surfaces. Properdin stabilizes the C3bBb complex, extending its half-life and enhancing amplification. The balance between amplification and regulation determines whether the pathway proceeds to downstream effector functions.
C5 convertase formation and membrane attack complex
In simple terms: The pathway then builds a second enzyme that starts the assembly of a pore-forming complex to punch holes in target cells.
When C3b deposits in sufficient density, it associates with the C3 convertase to form the C5 convertase (C3bBbC3b), which cleaves C5 into C5a and C5b [3,4]. C5a is a potent anaphylatoxin and chemoattractant, while C5b initiates assembly of the membrane attack complex (MAC) with C6, C7, C8, and C9. The MAC inserts into lipid bilayers and causes direct lysis of susceptible microbes and cells. This terminal step links GO:0006957 to direct killing of microbes and to tissue injury in disease.
Regulation by complement inhibitors
In simple terms: Brakes on the pathway prevent it from attacking our own cells.
Factor H competes with factor B for C3b binding and acts as a cofactor for factor I-mediated cleavage of C3b, thereby shutting down the convertase. Membrane cofactor protein (MCP, CD46) and decay-accelerating factor (DAF, CD55) protect host cells by promoting C3b inactivation and dissociating convertases. CD59 blocks MAC assembly on host membranes. Dysregulation of these inhibitors is associated with diseases such as thrombotic microangiopathy and lupus nephritis [2,8].
Crosstalk with inflammation and thrombosis
In simple terms: The alternative pathway also talks to the clotting and inflammation systems, which is why it matters in diseases like COVID-19.
Alternative pathway activation modulates inflammation in thoracic aortic aneurysm/dissection, suggesting crosstalk with vascular inflammatory signaling. In COVID-19, unusually large von Willebrand factor multimers provide a platform for AP activation under cytokine storm, contributing to microthrombosis. In lupus nephritis, AP activation is associated with thrombotic microangiopathy and predicts renal outcome [2,8]. These observations position GO:0006957 at the interface of complement, coagulation, and inflammation [1,7].
Key Genes Involved in GO:0006957 complement activation, alternative pathway
The following genes and proteins are central to the initiation, amplification, regulation, and effector functions of the alternative pathway of complement (GO:0006957).
| Gene | Major Role | Research Relevance |
|---|---|---|
| C3 | Central component; tickover substrate and source of C3b | Knockout and point-mutation models to study initiation and amplification |
| CFB (Factor B) | Forms C3 convertase with C3b; cleaved by factor D | Target for inhibiting AP amplification [4,6] |
| CFD (Factor D) | Serine protease that cleaves factor B | Rate-limiting enzyme; knockout models reduce AP activity [3,4] |
| CFH (Factor H) | Cofactor for factor I; decays C3 convertase | Mutations linked to aHUS and AMD; key regulator |
| CFI (Factor I) | Cleaves C3b in presence of cofactors | Regulatory node; deficiency causes uncontrolled AP |
| CFP (Properdin) | Stabilizes C3bBb convertase | Positive regulator; knockout reduces AP amplification |
| CD46 (MCP) | Membrane cofactor for factor I | Protects host cells; relevant to renal disease |
| CD55 (DAF) | Decay-accelerating factor; dissociates convertases | Host protection; knockout increases susceptibility |
| CD59 | Blocks MAC assembly | Terminal regulator; relevant to lysis |
| C5 | Cleaved to C5a and C5b by C5 convertase | Therapeutic target; links to inflammation |
| C5AR1 | Receptor for C5a | Mediates inflammatory signaling |
| C6 | MAC component | Terminal pathway effector |
| C7 | MAC component | Terminal pathway effector |
| C8 | MAC component | Terminal pathway effector |
| C9 | MAC component; forms pore | Direct lysis effector |
| VWF | Platform for AP activation in COVID-19 microthrombosis | Links AP to thrombosis |
| CR1 (CD35) | Receptor for C3b; regulates complement | Immune complex clearance |
How Is complement activation, alternative pathway Regulated?
The alternative pathway is tightly regulated at multiple steps to prevent host tissue damage. Factor H and factor I inactivate C3b, while MCP and DAF accelerate decay of the C3 convertase on host membranes. Properdin stabilizes the convertase and enhances amplification, representing a positive regulatory arm. CD59 prevents MAC assembly on host cells. In disease states, this balance can be disrupted; for example, AP activation in lupus nephritis is associated with thrombotic microangiopathy and poor renal outcome [2,8]. Low-molecular-weight inhibitors of the AP are being developed to pharmacologically restore this balance. Cytokine storm conditions in COVID-19 can promote AP activation on VWF multimers, further illustrating context-dependent regulation.
complement activation, alternative pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CFH | Atypical hemolytic uremic syndrome; AMD | Knockout or point-mutation iPSC-derived renal cells |
| C3 | Lupus nephritis; thrombotic microangiopathy | CRISPR knockout in podocytes or endothelial cells [2,8] |
| CFB | AP amplification in inflammatory disease | Overexpression and knockout in macrophages [4,6] |
| VWF | COVID-19 microthrombosis | Knock-in of VWF multimers in endothelial cells |
| CFP | Thoracic aortic aneurysm/dissection | Knockout in vascular smooth muscle cells |
Lupus nephritis and thrombotic microangiopathy
Alternative pathway activation is a key feature of lupus nephritis and is associated with thrombotic microangiopathy in these patients. AP activation predicts renal outcome, suggesting that measuring AP components could help stratify patients at risk of progressive kidney disease. These findings support the AP as both a biomarker and a therapeutic target in lupus nephritis [2,8].
Thoracic aortic aneurysm and dissection
Activation of the alternative complement pathway modulates inflammation in thoracic aortic aneurysm/dissection, indicating a role for GO:0006957 in vascular remodeling and inflammatory injury. This link suggests that AP inhibitors or genetic models could be explored to reduce aortic inflammation.
COVID-19 microthrombosis
In COVID-19, unusually large von Willebrand factor multimers serve as a platform for alternative pathway activation under cytokine storm, contributing to microthrombosis. This mechanism connects complement activation to the thrombotic complications of severe COVID-19 and highlights the AP as a potential intervention point.
Therapeutic targeting of the alternative pathway
Low-molecular-weight inhibitors of the alternative complement pathway are being developed, reflecting the growing recognition of AP-driven diseases. These inhibitors may offer advantages in diseases where AP amplification dominates, such as lupus nephritis and thrombotic microangiopathy [2,6,8].
From complement activation, alternative pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of CFH cause uncontrolled AP activation? | CFH knockout cell line |
| Does a point mutation in C3 alter tickover? | C3 point-mutation knock-in |
| Can tagged C3 track convertase assembly? | C3 knock-in with fluorescent tag |
| Does CFB overexpression amplify AP in disease cells? | CFB overexpression in macrophages [4,6] |
| Does CFP knockout reduce aortic inflammation? | CFP knockout in vascular smooth muscle cells |
| Does VWF multimers promote AP activation? | VWF knock-in in endothelial cells |
How to Study the complement activation, alternative pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Hemolysis assay | AP-mediated lysis | Functional validation of AP genes |
| C3b deposition ELISA | Surface C3b deposition | Quantifying AP amplification |
| RNA-seq | Expression of AP genes | Disease profiling [1,8] |
| Proteomics | Protein levels of complement components | Biomarker discovery |
| Flow cytometry | C3b and MAC on cells | Cell surface AP activation |
| Immunofluorescence | Tissue localization of complement | Vascular and renal pathology |
| CRISPR knockout screen | Genes modifying AP activity | Pathway discovery |
| Bioinformatics network analysis | Complement gene interactions | Data interpretation |
Functional complement assays
Hemolysis assays and C3b deposition assays measure AP activity directly and are used to validate genetic models of GO:0006957 [3,4]. These assays can be performed on serum or on cell surfaces to assess amplification and regulation.
Transcriptomic and proteomic profiling
RNA-seq and proteomics can quantify expression of AP genes such as C3, CFB, CFD, CFH, and CFI in disease models [1,2,8]. These approaches help link genotype to pathway activity and identify biomarkers.
CRISPR screening and bioinformatics
Genome-wide CRISPR knockout screens can identify genes that modify AP activation or complement-mediated killing. Bioinformatics analysis of complement gene networks can reveal regulatory hubs and disease associations.
Imaging and flow cytometry
Flow cytometry can detect C3b and MAC deposition on cell surfaces, while immunofluorescence can localize complement components in tissues [1,7]. These methods are useful for studying AP activation in vascular and renal disease models [1,2].
How CRISPR Can Be Used to Study GO:0006957 complement activation, alternative pathway
Knockout
CRISPR knockout of AP genes such as CFH, CFB, or C3 can reveal their causal role in complement activation and disease phenotypes [4,6]. For example, CFH knockout cells show enhanced C3b deposition and convertase activity.
Point Mutation
Point mutations in C3 or CFH can model disease-associated variants and test their impact on tickover, convertase stability, or regulation [3,4]. These models are valuable for understanding genotype-phenotype relationships in AP-driven diseases [2,8].
Knock-in
Knock-in of tagged C3 or CFB allows real-time tracking of convertase assembly and localization in live cells. Tagged knock-ins can also be used to study AP activation on specific surfaces such as VWF multimers.
Overexpression
Overexpression of CFB or C3 can amplify AP activity and model inflammatory states in macrophages or endothelial cells [4,6]. These models help test whether increased AP tone is sufficient to drive disease-related phenotypes [1,7].
How EDITGENE Supports complement activation, alternative pathway Research
Researchers studying complement activation, alternative pathway-related genes often need to determine whether a candidate gene is causally involved in AP activation, regulation, or disease progression. EDITGENE provides CRISPR-based cell model services that enable precise genetic manipulation of AP genes in relevant cell types, from knockout to knock-in and overexpression.
Contact EDITGENE today to design your custom CRISPR model for complement activation, alternative pathway research.
Frequently Asked Questions About complement activation, alternative pathway
What is complement activation, alternative pathway (GO:0006957)?
It is the biological process by which the alternative pathway of complement is initiated and amplified without antibodies, leading to direct killing of microbes and regulation of other immune processes [3,4].
What genes are involved in complement activation, alternative pathway?
Key genes include C3, CFB, CFD, CFH, CFI, CFP, CD46, CD55, CD59, C5, C6, C7, C8, and C9 [3,4].
How is the alternative pathway initiated?
It is initiated by tickover, the spontaneous hydrolysis of C3 to C3(H2O), which forms a fluid-phase C3 convertase with factor B and factor D.
What is the role of factor H in the alternative pathway?
Factor H is a key regulator that competes with factor B for C3b binding and acts as a cofactor for factor I-mediated C3b inactivation.
How does the alternative pathway contribute to lupus nephritis?
AP activation is associated with thrombotic microangiopathy in lupus nephritis and predicts renal outcome, making it a potential biomarker and therapeutic target [2,8].
Is the alternative pathway involved in COVID-19 microthrombosis?
Yes, unusually large von Willebrand factor multimers provide a platform for AP activation under cytokine storm, contributing to microthrombosis.
What experimental models are used to study GO:0006957?
CRISPR knockout, point-mutation, knock-in, and overexpression cell models, along with hemolysis assays and C3b deposition assays, are commonly used [3,4,6].
Can the alternative pathway be inhibited therapeutically?
Low-molecular-weight inhibitors of the alternative complement pathway are being developed for complement-driven diseases.
What is the difference between the alternative and classical complement pathways?
The alternative pathway is antibody-independent and initiated by spontaneous C3 tickover, whereas the classical pathway is typically triggered by antibody-antigen complexes [3,4].
How can CRISPR screens help study the alternative pathway?
Genome-wide CRISPR screens can identify genes that modify AP activation or complement-mediated killing, revealing new regulatory nodes.
Conclusion
GO:0006957, complement activation, alternative pathway, is a fundamental biological process that provides antibody-independent immune defense and amplifies complement activity in health and disease [3,4]. Its dysregulation is linked to lupus nephritis, thrombotic microangiopathy, thoracic aortic aneurysm/dissection, and COVID-19 microthrombosis, making it an important therapeutic target [1,2,7,8]. CRISPR-based cell models are powerful tools for dissecting the causal roles of AP genes and for testing candidate inhibitors. By combining functional assays, omics, and genome editing, researchers can advance our understanding of this pathway and translate findings into clinical applications.
References
- 1. Piao C et al.. 2024. Activation of the alternative complement pathway modulates inflammation in thoracic aortic aneurysm/dissection.. Am J Physiol Cell Physiol 326(2):C647-C658 PMID: 38189133
- 2. Mejia-Vilet JM et al.. 2021. Alternative complement pathway activation in thrombotic microangiopathy associated with lupus nephritis.. Clin Rheumatol 40(6):2233-2242 PMID: 33170371
- 3. Pangburn MK. 2023. Initiation of the alternative pathway of complement and the history of "tickover".. Immunol Rev 313(1):64-70 PMID: 36089768
- 4. Harrison RA et al.. 2023. The complement alternative pathway in health and disease-activation or amplification?. Immunol Rev 313(1):6-14 PMID: 36424888
- 6. Schubart A et al.. 2023. Low-molecular weight inhibitors of the alternative complement pathway.. Immunol Rev 313(1):339-357 PMID: 36217774
- 7. Fujimura Y et al.. 2022. COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm.. Int J Hematol 115(4):457-469 PMID: 35316498
- 8. Kim H et al.. 2020. Activation of the alternative complement pathway predicts renal outcome in patients with lupus nephritis.. Lupus 29(8):862-871 PMID: 32408850
